Is this email not displaying correctly?
View it in your browser.
Newswise - News for Journalists

Newswise Special Wire
Tuesday, March 22, 2016

Public edition |

Newswise Cancer Research Wire for 22-Mar-2016

Cancer Research Wire

Cancer research news for the public and news media. More stories can be found at the Newswise Cancer News Source.

New Treatment Reduces Precancerous Polyps in Hereditary Cancer Patients

Inheriting a mutation in the APC gene leads to a nearly 100% lifetime risk of colorectal cancer. While colon cancer can be kept at bay by removing the large intestine, these patients also have up to a 15% risk of getting cancer in the small intestine, which is the leading cause of cancer death in this patient group. A new study published in the Journal of the American Medical Association (JAMA), has identified the first prevention treatment for these patients, a two-drug combination that significantly reduces the number and size of precancerous polyps in the small intestine.

 • Image(s) embedded •  (Embargo expired on 22-Mar-2016 at 11:00 ET)

Journal of the American Medical Association; CA073992; CA042014; TR001067

– Huntsman Cancer Institute at the University of Utah

New Prevention Treatment for Those At Risk for Cancerous Polyps, Many Targeted Cancer Therapies Suppress T Cell Immune Responses, High-Risk Lung Cancer Patients May Not Need Annual Screenings, and more in the Cancer News Source

See the latest cancer research and get pertinent informative features on the fight against cancer at Newswise's Cancer News Source.

– Newswise

Lymphoma Overrides a Key Protein’s Quadruple Locks

Protein chemists at Johns Hopkins report they are closer to explaining why certain blood cancers are able to crack a molecular security system and run rampant.

Journal of Biological Chemistry, Apr-2016; Journal of Biological Chemistry, Apr-2016; R01CA177600

– Johns Hopkins Medicine

Many Targeted Cancer Therapies Suppress T Cell Immune Responses

New research from The Wistar Institute demonstrated that dozens of these targeted therapies suppressed the activity of T cells that could actually help fight tumors. While studying the FDA-approved targeted therapy trametinib, the researchers also found that pairing it with a signaling protein “superagonist” stimulated T cell activity while preserving the cancer-blocking effects of the cancer treatment.

 • Image(s) embedded • 

Cancer Research, March-2016

– Wistar Institute

Protecting the Pancreas: Compound Fights Fibrosis in Animal Model

SLU scientists identify a group of proteins as new and important players in the mechanism that causes pancreatic scarring, which is associated with chronic pancreatitis.

 • Image(s) embedded • 

Cellular and Molecular Gastroenterology and Hepatology online March 16, 2016

– Saint Louis University Medical Center

Mount Sinai First Hospital to Treat Liver Cancer with Radiopaque Bead

M1 LUMI™ Bead provides visible confirmation during embolization treatment for liver cancer

– Mount Sinai Health System

A Healthy Gut Could Help Prevent Deadly Side Effect of Bone Marrow Transplant

Researchers found a metabolite in the gut microbiome could impact outcomes after bone marrow transplant. Butyrate was significantly reduced in the intestinal tract of experimental mice that received bone marrow transplant. When the researchers increased butyrate in these mouse models, they saw a decrease in the incidence and severity of graft vs. host disease.

 • Image(s) embedded •  (Embargo expired on 21-Mar-2016 at 12:00 ET)

Nature Immunology; HL-090775; HL-128046; CA-173878

– University of Michigan Health System

UCLA Study Uncovers Key New Insights Into How Cells Are Wired to Survive Radiation Therapy

A UCLA-led study has for the first time shown that microRNAs, specifically the microRNA known as miR-34, can sit silently in an inactive state in a cell waiting for a signal to turn it on. The discovery turns on its head the long-held notion that a microRNA when made is always already activated and ready to work, and shows for the first time that microRNAs can be controlled in a way similar to proteins, waiting for stress signals to turn them on.

 • Image(s) embedded •  (Embargo expired on 21-Mar-2016 at 03:00 ET)

the journal Nature Communications, March 21

– University of California, Los Angeles (UCLA), Health Sciences

Increased Travel Burden Associated with Decreased Likelihood of Receiving Radiation Therapy to Treat Rectal Cancer

Increased travel distance to a cancer treatment facility negatively impacts the likelihood that patients with stage II/III rectal cancer will receive radiation therapy (RT) to treat their disease, according to a study analyzing 26,845 patient records from the National Cancer Data Base (NCDB) that was published in the March 2016 issue of International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).

International Journal of Radiation Oncology Biology Physics, Mar-2016

– American Society for Radiation Oncology (ASTRO)

Interventions Required to Reduce Non-Cancer-Related Hospitalizations for Elderly Men After Prostate Cancer Diagnosis, Study Finds

A new study published in the February issue of JNCCN finds that men older than 67 who are diagnosed with prostate cancer are 37 percent more likely to have non-cancer-related hospitalization after diagnosis than before diagnosis, pointing to the need to better manage non-cancer conditions after a cancer diagnosis.

 • Image(s) embedded • 

J Natl Compr Canc Netw 2016;14:186-194

– National Comprehensive Cancer Network® (NCCN®)

UGA Researchers Find Potential Treatment for Prostate Cancer

University of Georgia researchers have created a new therapeutic for prostate cancer that has shown great efficacy in mouse models of the disease. The treatment is designed to inhibit the activity of a protein called PAK-1, which contributes to the development of highly invasive prostate cancer cells.

 • Image(s) embedded • 

Nanomedicine: Nanotechnology, Biology and Medicine

– University of Georgia

High-Risk Lung Cancer Patients May Not Need Annual Screenings

Most high-risk lung cancer patients might not need annual low-dose computed tomography (LDCT) screenings if they are cleared of disease in their initial test, according to a study led by a Duke Cancer Institute researcher.

 • Image(s) embedded • 

Lancet Oncology

– Duke Health

Mayo Clinic Expert Shares Five Things to Know About Colorectal Cancer

Roughly 140,000 people are diagnosed with colorectal cancer in the United States each year. It is the third most common cancer and No. 2 cause of cancer-related deaths among men and women.

– Mayo Clinic

New Compound Is Effective Against Drug-Resistant Leukemia, Preclinical Study Finds

Researchers at UNC Lineberger Comprehensive Cancer Center, UNC Eshelman School of Pharmacy, the Aflac Cancer & Blood Disorders Center in Atlanta, Emory University School of Medicine, and at other institutions report that a novel compound MRX-2843 more than doubled the median days of survival in laboratory models with a drug-resistant form of the acute myeloid leukemia.

JCI Insight, March-2016

– University of North Carolina Health Care System

Moffitt Pathologists Identify New Potential Target in Ovarian Serous Cancer

TAMPA, Fla. – Moffitt Cancer Center researchers discovered that patients with ovarian serous cancer and an overexpression of the HER4 protein are less likely to respond to chemotherapy and have a lower rate of survival. That’s according to a study Carolina Strosberg, M.D., is presenting this week at the 2016 United States and Canadian Academy of Pathology (USCAP) Annual Conference in Seattle, Washington.

– Moffitt Cancer Center

Is There a Metabolic Key to Deadliest Form of Ovarian Cancer?

n a study published in the international journal Journal of Cancer, researchers focused on the role of metabolic factors such as fasting glucose and body mass index (BMI), to determine their correlation to tumor stage at diagnosis. Results indicate an association between these metabolic measures and ovarian cancer which the authors believe worthy of further investigation.

International journal Journal of Cancer

– Sbarro Health Research Organization (SHRO)

For First Time, Scientists Use CRISPR-Cas9 to Target RNA in Live Cells

Scientists have long sought an efficient method for targeting RNA— intermediary genetic material that carries the genetic code from the cell’s nucleus to protein-making machinery — in living cells. Researchers at University of California, San Diego School of Medicine have now achieved this by applying the popular DNA-editing technique CRISPR-Cas9 to RNA. The study is published March 17 in <i>Cell</i>.

 • Image(s) embedded •  (Embargo expired on 17-Mar-2016 at 12:00 ET)


– University of California, San Diego Health Sciences

VCU Scientists Develop Computer Models Simulating Stem Cell Transplant Recovery

Scientists at Virginia Commonwealth University have developed computer models that can simulate the recovery of the immune system in patients undergoing stem cell transplants.

 • Image(s) embedded • 

Journal of the Royal Society Interface; P30 CA016059

– VCU Massey Cancer Center

New MD Anderson-Developed Breast Cancer Staging System Emphasizes Importance of Tumor Biology as Prognostic Indicator

A new breast cancer staging system developed by researchers at The University of Texas MD Anderson Cancer Center finds that incorporating tumor biology is a critical prognostic indicator for women who undergo neoadjuvant, or pre-surgical, therapy for breast cancer.

 • Image(s) embedded • 

JAMA Oncology; CA016672

– University of Texas M. D. Anderson Cancer Center

Neutralizing a Tumor’s Acidic Environment Improves Activity of Immune-Targeting Cancer Therapies

Cancer cells have the ability to grow in an acidic tumor environment that is detrimental to other cells, including immune cells. In a Cancer Research cover article published this week, Moffitt Cancer Center reported that neutralizing the acidic tumor environment increases the efficacy of several immune-targeting cancer therapies.

Cancer Research

– Moffitt Cancer Center

UT Southwestern Researchers Find New Cytoplasmic Role for Proteins Linked to Neurological Diseases, Cancers

Researchers at UT Southwestern Medical Center have identified a second role for a class of RNA-binding proteins, revealing new insights about neurological diseases and conditions associated with this protein such as autism, epilepsy, and certain types of cancer.

 • Image(s) embedded • 

Developmental Cell

– UT Southwestern Medical Center

Researchers Discover How RNA Editing May Promote Tumor Growth

A new study provides insight on the potential role played by RNA (ribonucleic acid) editing in cancer.

Scientific Reports

– Boston University Medical Campus

Genomic Profiling Helps Provide Targeted Therapy Options for Hard to Treat Cancers

Research from Rutgers Cancer Institute of New Jersey examining difficult to treat tumors through genomic profiling shows that tumors with alterations in a signaling pathway responsible for cell regulation may respond to targeted therapy regardless of where the tumor originated in the body.

 • Image(s) embedded •  (Embargo expired on 16-Mar-2016 at 16:30 ET)

AACR Annual Meeting 2016

– Rutgers Cancer Institute of New Jersey

Protecting U.S. Minors from Tanning Bed Exposure

In December 2015, the FDA proposed new restrictions related to tanning bed use, including banning their use among individuals younger than 18. As the comment period on the proposal winds down, a Rutgers Cancer Institute of New Jersey investigator who conducts research on tanning behaviors weighs in.

 • Image(s) embedded •  (Embargo expired on 16-Mar-2016 at 18:00 ET)

JAMA Dermatology, Mar-2016

– Rutgers Cancer Institute of New Jersey

Tips on Seeking a Thyroid Surgeon, How to Improve Cancer Immunotherapy, Drug Combination Shuts Down Tumor Growth in Aggressive Lung Cancer, and more in the Cancer News Source

Tips on Seeking a Thyroid Surgeon, How to Improve Cancer Immunotherapy, Drug Combination Shuts Down Tumor Growth in Aggressive Lung Cancer, and more in the Newswise Cancer News Source

– Newswise

Antibody Developed at Johns Hopkins Slows Tumor Growth and Metastasis in Mice

Johns Hopkins scientists report they have developed an antibody against a specific cellular gateway that suppresses lung tumor cell growth and breast cancer metastasis in transplanted tumor experiments in mice, according to a new study published in the February issue of Nature Communications.

Nature Communications; GM078579, MH084691, NS073611, NS050274

– Johns Hopkins Medicine

Higher Volume Radiation Facilities Associated with Better Survival Rates

New research finds improvement in overall survival rates among men with aggressive prostate cancer who were treated with radiation at a facility that frequently performs that treatment.

International Journal of Radiation Oncology, Biology, Physics

– Brigham and Women’s Hospital

Cancer-Causing Gene Triggered by Alcohol May Increase Breast Cancer Risk

A University of Houston researcher and his team have discovered an important link between alcohol and breast cancer by identifying a cancer-causing gene triggered by alcohol.


– University of Houston

Research Network Bringing Cervical Cancer Clinical Trials to Countries Where Disease Has High Burden

The Cervix Cancer Research Network (CCRN) is working to facilitate clinical trials of treatments of cancer of the cervix in countries where the disease has a high burden and national research groups have not yet been established.

– Loyola University Health System


Dr. Jeffrey Fowler Begins SGO Presidency

effrey Fowler, MD, John G. Boutselis Chair in Gynecologic Oncology and Professor and vice-chair of Obstetrics and Gynecology at The Ohio State University Wexner Medical Center in Columbus, started his one-year term as the 48th President of the Society of Gynecologic Oncology (SGO) today at the conclusion of the Society’s 47th Annual Meeting on Women’s Cancer in San Diego.

 • Image(s) embedded •  (Embargo expired on 22-Mar-2016 at 08:00 ET)

– Society of Gynecologic Oncology

Dr. Michael Birrer Named Recipient of the 2016 Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher

The Claudia Cohen Research Foundation and the Foundation for Women’s Cancer announced today that Michael J. Birrer, MD, PhD, has been selected as the 2016 recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Researcher.

 • Image(s) embedded •  (Embargo expired on 21-Mar-2016 at 08:00 ET)

– Society of Gynecologic Oncology

Scripps Florida Scientists Win $1.4 Million Grant to Develop New Ways to Block Breast Cancer

Scientists from the Florida campus of The Scripps Research Institute have received a $1.4 million grant from the Department of Defense to develop a series of drug candidates that act against molecules closely linked with the growth of cancer cells.

 • Image(s) embedded • 


– Scripps Research Institute

Two MD Anderson Faculty Members Honored with Highest Distinctions From ASCO

The American Society of Clinical Oncology (ASCO) will recognize two physician-scientists from The University of Texas MD Anderson Cancer Center with two of its highest distinctions at its annual meeting in Chicago.

 • Image(s) embedded • 

– University of Texas M. D. Anderson Cancer Center

Making Cancer History®: Free Seminar Comes to Midland

The University of Texas MD Anderson Cancer Center brings its signature Making Cancer History® seminar to Midland, for the first time, 11:30 a.m. to 1:30 p.m., Tuesday, April 12, at the Midland Country Club, 6101 N. Highway 349.

 • Image(s) embedded • 

– University of Texas M. D. Anderson Cancer Center

Higher Education Events

Cancer Care in an Election Year, Palliative Care Challenges, Incorporating Patient Values, and Guidelines Updates Featured at NCCN Annual Conference

Approximately 1,700 oncology stakeholders are expected to attend NCCN’s 21st Annual Conference: Advancing the Standard of Cancer Care™, March 31 – April 2, 2016, in Hollywood, Florida.

 • Image(s) embedded • 

– National Comprehensive Cancer Network® (NCCN®)

subscribe/unsubscribe :: edit my preferences
© 2016 Newswise, Inc. All Rights Reserved. | 215 E. 5th St. SW, Charlottesville VA 22903 | 434-296-9417 | Contact Us